MA42134A - Conjugués peptides/oligonucléotides - Google Patents
Conjugués peptides/oligonucléotidesInfo
- Publication number
- MA42134A MA42134A MA042134A MA42134A MA42134A MA 42134 A MA42134 A MA 42134A MA 042134 A MA042134 A MA 042134A MA 42134 A MA42134 A MA 42134A MA 42134 A MA42134 A MA 42134A
- Authority
- MA
- Morocco
- Prior art keywords
- peptides
- oligonucleotides conjugates
- conjugates
- oligonucleotides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562163960P | 2015-05-19 | 2015-05-19 | |
| US201662337536P | 2016-05-17 | 2016-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42134A true MA42134A (fr) | 2018-03-28 |
Family
ID=57320822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042134A MA42134A (fr) | 2015-05-19 | 2016-05-19 | Conjugués peptides/oligonucléotides |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10675356B2 (fr) |
| EP (2) | EP3297649B1 (fr) |
| JP (2) | JP6954843B2 (fr) |
| KR (2) | KR20240035901A (fr) |
| CN (2) | CN114681621B (fr) |
| AU (1) | AU2016264471B2 (fr) |
| CA (1) | CA2986228A1 (fr) |
| DK (1) | DK3297649T5 (fr) |
| ES (1) | ES2964695T3 (fr) |
| FI (1) | FI3297649T3 (fr) |
| HK (1) | HK1252759A1 (fr) |
| HR (1) | HRP20231431T1 (fr) |
| IL (1) | IL255655B (fr) |
| MA (1) | MA42134A (fr) |
| MX (1) | MX388743B (fr) |
| NZ (1) | NZ737757A (fr) |
| WO (1) | WO2016187425A1 (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016264471B2 (en) * | 2015-05-19 | 2022-01-27 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| GB2545898B (en) * | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| MX2018016253A (es) | 2016-07-05 | 2019-09-09 | Biomarin Tech Bv | Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos. |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| KR102279333B1 (ko) | 2017-03-07 | 2021-07-20 | 주식회사 만도 | 차량의 디스플레이 시스템 및 이의 구동 방법 |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB2580569B (en) * | 2017-06-28 | 2021-08-18 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| MX2020003130A (es) * | 2017-09-22 | 2020-09-25 | Avidity Biosciences Inc | Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos. |
| EP3691657A4 (fr) | 2017-10-04 | 2021-07-21 | Avidity Biosciences, Inc. | Compositions d'acide nucléique-polypeptide et utilisations de celles-ci |
| US12502432B2 (en) | 2017-10-17 | 2025-12-23 | Sarepta Therapeutics, Inc. | Bicyclic peptide oligonucleotide conjugates |
| AU2018378812B2 (en) | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| JP7564087B2 (ja) * | 2018-07-30 | 2024-10-08 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス送達のための三量体ペプチド |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| CA3108282A1 (fr) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| WO2020219820A1 (fr) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Compositions d'acide nucléique et méthodes de saut multi-exon |
| US12006499B2 (en) | 2019-06-06 | 2024-06-11 | Avidity Biosciences, Inc. | Una amidites and uses thereof |
| CN114375296A (zh) | 2019-06-06 | 2022-04-19 | 艾维迪提生物科学公司 | 核酸多肽组合物及其用途 |
| CN114901823A (zh) | 2019-12-26 | 2022-08-12 | 日本新药株式会社 | 诱导外显子50的跳读的反义核酸 |
| IL295967A (en) | 2020-02-28 | 2022-10-01 | Nippon Shinyaku Co Ltd | Antisense nucleic acids for splicing on exon 51 |
| WO2021188390A1 (fr) | 2020-03-19 | 2021-09-23 | Avidity Biosciences, Inc. | Compositions et méthodes de traitement d'une dystrophie musculaire facio-scapulo-humérale |
| EP4314298A1 (fr) * | 2021-04-02 | 2024-02-07 | Avidity Biosciences, Inc. | Conjugué anticorps-oligonucléotide et compositions conjuguées anticorps-peptide-oligonucléotide et méthodes d'induction de saut d'exon |
| WO2022270585A1 (fr) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | Combinaison d'oligomères antisens |
| CA3225573A1 (fr) | 2021-07-08 | 2023-01-12 | Nippon Shinyaku Co., Ltd. | Inhibiteur de precipitation |
| CN118475355A (zh) | 2021-07-08 | 2024-08-09 | 日本新药株式会社 | 肾毒性减轻剂 |
| TW202308664A (zh) | 2021-07-08 | 2023-03-01 | 日商日本新藥股份有限公司 | 腎毒性減輕劑 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL310185A (en) | 2021-07-16 | 2024-03-01 | Academisch Ziekenhuis Leiden | Oligonucleotide for inhibiting quaking activity |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| WO2023171804A1 (fr) | 2022-03-10 | 2023-09-14 | 日本新薬株式会社 | Oligomère antisens antiviral |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| IL316802A (en) | 2022-05-06 | 2025-01-01 | Academisch Ziekenhuis Leiden | Oligonucleotide |
| WO2024069235A2 (fr) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions contenant des oligonucléotides ayant des applications théranostiques |
| WO2025007907A1 (fr) * | 2023-07-04 | 2025-01-09 | 大睿生物 | Ligand d'administration d'oligonucléotide contenant un peptide |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| WO1986005519A1 (fr) | 1985-03-15 | 1986-09-25 | James Summerton | Reactif et procede d'analyse de polynucleotides |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| RU2606627C2 (ru) | 2007-11-15 | 2017-01-10 | Серепта Терапьютикс,Инк. | Способ синтеза морфолиновых олигомеров |
| US8394621B2 (en) * | 2008-10-23 | 2013-03-12 | Matrix Genetrics, LLC | Modified photosynthetic microorganisms for producing triglycerides |
| BR122020021379B1 (pt) * | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US9334495B2 (en) * | 2009-11-25 | 2016-05-10 | Elitechgroup B.V. | Minor groove binder (MGB)-oligonucleotide miRNA antagonists |
| JP6025567B2 (ja) * | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療 |
| ES2607603T3 (es) | 2010-09-30 | 2017-04-03 | Nippon Shinyaku Co., Ltd. | Derivado de ácido morfolino nucleico |
| AU2012246822B2 (en) * | 2011-04-22 | 2017-05-25 | Biomarin Technologies B.V. | New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1) |
| CA3092114A1 (fr) * | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Conjugues peptides/oligonucleotides |
| US10066228B2 (en) * | 2011-11-30 | 2018-09-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| ES2935606T3 (es) * | 2011-12-08 | 2023-03-08 | Sarepta Therapeutics Inc | Análogos de oligonucleótidos dirigidos a LMNA humana |
| CN104411831B (zh) * | 2012-03-20 | 2020-08-11 | 萨勒普塔医疗公司 | 寡核苷酸类似物的硼酸缀合物 |
| EP2870246B1 (fr) * | 2012-07-03 | 2019-09-11 | BioMarin Technologies B.V. | Oligonucléotide pour le traitement de patients atteints de dystrophie musculaire |
| EP2900821B1 (fr) * | 2012-09-25 | 2020-04-01 | Genzyme Corporation | Oligonucléotides morpholinos antisens liés à un peptide pour traiter la dystrophie myotonique |
| US20140329762A1 (en) | 2013-03-15 | 2014-11-06 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| EP3262056A4 (fr) | 2015-02-27 | 2018-09-19 | Sarepta Therapeutics, Inc. | Inclusion de l'exon 2, induite par antisens, dans une alpha-glucosidase acide |
| AU2016264471B2 (en) * | 2015-05-19 | 2022-01-27 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
-
2016
- 2016-05-19 AU AU2016264471A patent/AU2016264471B2/en active Active
- 2016-05-19 FI FIEP16797300.7T patent/FI3297649T3/fi active
- 2016-05-19 MX MX2017014806A patent/MX388743B/es unknown
- 2016-05-19 WO PCT/US2016/033276 patent/WO2016187425A1/fr not_active Ceased
- 2016-05-19 CN CN202210279461.1A patent/CN114681621B/zh active Active
- 2016-05-19 ES ES16797300T patent/ES2964695T3/es active Active
- 2016-05-19 KR KR1020247007058A patent/KR20240035901A/ko active Pending
- 2016-05-19 DK DK16797300.7T patent/DK3297649T5/da active
- 2016-05-19 HR HRP20231431TT patent/HRP20231431T1/hr unknown
- 2016-05-19 CN CN201680041867.9A patent/CN107921092B/zh active Active
- 2016-05-19 HK HK18112084.2A patent/HK1252759A1/zh unknown
- 2016-05-19 CA CA2986228A patent/CA2986228A1/fr active Pending
- 2016-05-19 NZ NZ737757A patent/NZ737757A/en unknown
- 2016-05-19 EP EP16797300.7A patent/EP3297649B1/fr active Active
- 2016-05-19 JP JP2017560238A patent/JP6954843B2/ja active Active
- 2016-05-19 EP EP23195508.9A patent/EP4306538A3/fr active Pending
- 2016-05-19 US US15/574,734 patent/US10675356B2/en active Active
- 2016-05-19 MA MA042134A patent/MA42134A/fr unknown
- 2016-05-19 KR KR1020177035825A patent/KR102644053B1/ko active Active
-
2017
- 2017-11-14 IL IL255655A patent/IL255655B/en unknown
-
2020
- 2020-04-28 US US16/860,292 patent/US11097011B2/en active Active
- 2020-11-05 JP JP2020185083A patent/JP2021011505A/ja active Pending
-
2021
- 2021-08-16 US US17/403,403 patent/US11672871B2/en active Active
-
2023
- 2023-04-06 US US18/296,697 patent/US12239715B2/en active Active
-
2025
- 2025-01-17 US US19/029,784 patent/US20260014263A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42134A (fr) | Conjugués peptides/oligonucléotides | |
| IL255217A0 (en) | Cancer neoepitopes | |
| EP3313857A4 (fr) | Conjugués polymère-cyclodextrine-lipide | |
| LT3525830T (lt) | Pirolbenzodiazepino konjugatai | |
| EP3408391A4 (fr) | Oligonucléotides ramifiés | |
| DK3268047T3 (da) | Amatoxin/antistof-konjugater | |
| DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
| EP3314027A4 (fr) | Oligonucléotides thérapeutiques | |
| IL254516A0 (en) | Proteins specific for cd137 | |
| DK3723783T3 (da) | Mitokondrie-målrettede peptider | |
| EP3328873A4 (fr) | Oligonucléotides ciblés | |
| DK3119885T3 (da) | Antistof-fynomer-konjugater | |
| LT3544636T (lt) | Pirolobenzodiazepino-antikūno konjugatai | |
| DK3148591T3 (da) | Nanopartikel-lægemiddelkonjugater | |
| DK3067559T3 (da) | Inflator | |
| EP3355931C0 (fr) | Conjugués de protéines | |
| DK3612537T3 (da) | Pyrrolobenzodiazepinkonjugater | |
| IL284753A (en) | Oligonucleotide peptide conjugates | |
| PL3316885T3 (pl) | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a | |
| IL253549B (en) | Antibody-urease conjugates for therapeutic purposes | |
| DK3544634T3 (da) | MET-antistof-lægemiddelkonjugater | |
| EP3619311C0 (fr) | Assemblage d'adn | |
| DK3448879T3 (da) | Claudin-6 peptider | |
| DK3329004T3 (da) | Terapeutiske oligonukleotider | |
| HRP20181164T1 (hr) | Fluorescentni konjugati |